<DOC>
	<DOCNO>NCT02037477</DOCNO>
	<brief_summary>The purpose study investigate acid-inhibitory effect multiple oral dos Vonoprazan ( TAK-438 ) relative effect vonoprazan versus two control ( esomeprazole rabeprazole sodium ) healthy Japanese adult male participant CYP2C19 extensive metabolizer ( EM ) genotype .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Acid-Inhibitory Effect Multiple Oral Doses Vonoprazan ( TAK-438 )</brief_title>
	<detailed_description>This Phase 3 open-label crossover study evaluate acid-inhibitory effect follow 7 day multiple dos vonoprazan ( 20 mg per dose ) esomeprazole ( 20 mg per dose ) ( Cohort 1 ) vonoprazan ( 20 mg per dose ) rabeprazole sodium ( 10 mg per dose ) ( Cohort 2 ) healthy Japanese adult male participant ( CYP2C19 genotype : EM ) . There total 20 participant , 5 per group Cohorts 1 2 . At least 2 participant homo EM ( *1/*1 ) hetero EM ( *1/*2 , *1/*3 ) CYP2C19 genotype enrol among 5 participant per group . The drug test study call vonoprazan . This study look acid inhibitory effect follow 7 day multiple dos vonoprazan esomeprazole ( Cohort 1 ) vonoprazan rabeprazole sodium ( Cohort 2 ) healthy Japanese adult male participant CYP2C19 EM genotype . The study enroll total 20 participant , 5 per group Cohorts . At least 2 participant homo EM ( *1/*1 ) hetero EM ( *1/*2 , *1/*3 ) CYP2C19 genotype enrol among 5 participant per group . - Group A , Cohort 1 : vonoprazan ( 20 mg per dose 7 day ) follow esomeprazole ( 20 mg per dose 7 day ) - Group B , Cohort 1 : esomeprazole ( 20 mg per dose 7 day ) follow TAK-438 ( 20 mg per dose 7 day ) - Group C , Cohort 2 : vonoprazan ( 20 mg per dose 7 day ) follow rabeprazole sodium ( 10 mg per dose 7 day ) - Group D , Cohort 2 : rabeprazole sodium ( 10 mg per dose 7 day ) follow vonoprazan ( 20 mg per dose 7 day ) . All participant ask take Study Medication time day throughout study . This single center trial conduct Japan . The overall time participate study 31 day .</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1 . Is healthy Japanese adult male volunteer . 2 . Is age 20 45 year , inclusive , time informed consent . 3 . Has confirm CYP2C19 genotyping Extensive Metabolizer [ EM ( *1/*1 , *1/*2 , *1/*3 ) ] . 4 . Capable understand comply protocol requirement . 5 . The participant sign date write informed consent form prior initiation study procedure . 6 . Weighs 50 kg body mass index ( BMI ) 18.5 less 25.0 kg/m^2 Screening admission ( Day 3 ) . 7 . H. pylorinegative Screening . 1 . Has undergone resection upper gastrointestinal tract vagotomy . 2 . Was determine hypoacidity anacidity . 3 . Has present past history acidrelated disease ( reflux esophagitis , gastric ulcer , duodenal ulcer , nonerosive gastroesophageal reflux , Barrett 's esophagus , ZollingerEllison syndrome , etc. ) . 4 . Has undergone eradication H. pylorus within 6 month prior start study drug administration . 5 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality may impact ability subject participate potentially confound study result . 6 . Has know hypersensitivity allergy drug food . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 5 year prior start study drug administration . 8 . Has poor peripheral venous access . 9 . Had 200 mL whole blood drawn within 4 week ( 28 day ) prior start study drug administration 400 mL whole blood drawn within 12 week ( 84 day ) prior start study drug administration . 10 . Had total volume 800 mL whole blood drawn within 52 week ( 364 day ) prior start study drug administration . 11 . Has undergone blood component draw within 2 week ( 14 day ) prior start study drug administration . 12 . Requires treatment exclude medication specify study require nutrition vitamin supplement food prohibit study . 13 . Has receive study medication within 16 week ( 112 day ) prior start study drug administration . 14 . Has receive vonoprazan ( TAK438 ) past . 15 . Has history cancer . 16 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen serological reaction syphilis Screening . 17 . Has Screening admission ( Day 3 ) abnormal clinically significant electrocardiogram ( ECG ) . 18 . Has abnormal Screening admission ( Day 3 ) laboratory value suggest clinically significant underlying disease subject follow lab abnormality : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; twice upper limit normal range . 19 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 20 . Participant , opinion investigator subinvestigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>